ArticleOncotarget2020
Clonality and antigen-specific responses shape the prognostic effects of tumor-infiltrating T cells in ovarian cancer.
Open access · diamondAbstract read
In one paragraph
Article in Oncotarget, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 21 citations in OpenAlex.
- Spatiotemporal immune heterogeneity and precision immunotherapy for ovarian cancer.Clinical and translational medicine · 2026Review
- Overcoming impaired antigen presentation in tumor-draining lymph nodes facilitates immunotherapy.Journal for immunotherapy of cancer · 2025Article
- Harnessing TCR repertoires: predictive insights and therapeutic monitoring in cancer immunotherapy.Immuno-oncology technology · 2025Review
- Overcoming impaired antigen presentation in tumor draining lymph nodes facilitates immunotherapy.bioRxiv : the preprint server for biology · 2025Article
- mTOR inhibition modulates vaccine-induced immune responses to generate memory T cells in patients with solid tumors.Journal for immunotherapy of cancer · 2025Article
- Single-cell long-read targeted sequencing reveals transcriptional variation in ovarian cancer.Nature communications · 2024Article
- Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies.Experimental hematology & oncology · 2024Review
- Immune Assessment Today: Optimizing and Standardizing Efforts to Monitor Immune Responses in Cancer and Beyond.Cancers · 2024Article
- Globally shared TCR repertoires within the tumor-infiltrating lymphocytes of patients with metastatic gynecologic cancer.Scientific reports · 2023Article
- Egress of resident memory T cells from tissue with neoadjuvant immunotherapy: Implications for systemic anti-tumor immunity.Oral oncology · 2023Review
- Neoantigens: promising targets for cancer therapy.Signal transduction and targeted therapy · 2023Review
- Carboplatin enhances lymphocyte-endothelial interactions to promote CD8Gynecologic oncology · 2023Article
- Review
- Tumor-associated Tregs obstruct antitumor immunity by promoting T cell dysfunction and restricting clonal diversity in tumor-infiltrating CD8+ T cells.Journal for immunotherapy of cancer · 2022Article
- Article
- Reframing How Physical Activity Reduces The Incidence of Clinically-Diagnosed Cancers: Appraising Exercise-Induced Immuno-Modulation As An Integral Mechanism.Frontiers in oncology · 2022Review
- TCR Clonality and Genomic Instability Signatures as Prognostic Biomarkers in High Grade Serous Ovarian Cancer.Cancers · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 1 country.
Takemasa TsujiCenter for Immunotherapy, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Kevin H EngBiostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Junko MatsuzakiCenter for Immunotherapy, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Sebastiano BattagliaCenter for Immunotherapy, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
J Brian SzenderDepartment of Gynecologic Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Anthony MiliottoCenter for Immunotherapy, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Sacha GnjaticTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Wiam BsharaDepartment of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Carl D MorrisonDepartment of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Shashikant LeleDepartment of Gynecologic Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Ryan O EmersonAdaptive Biotechnologies, Seattle, WA, USA.
Jianmin WangBiostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Song LiuBiostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Harlan RobinsAdaptive Biotechnologies, Seattle, WA, USA.
Amit A LugadeCenter for Immunotherapy, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Kunle OdunsiCenter for Immunotherapy, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Roswell Park Comprehensive Cancer Center · USAdaptive Biotechnologies (United States) · USIcahn School of Medicine at Mount Sinai · US
Funding
Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI Dean G. Tang · 1985 to 2026
$116.6MHigh-Dimensional Immune Monitoring of NCI-Supported Immunotherapy TrialsU24CA224319 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Sacha Gnjatic, Seunghee Kim-Schulze · 2017 to 2026
$21.5MRPCI-UPCI Ovarian Cancer SPOREP50CA159981 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MOYSICH, KIRSTEN B., ODUNSI, KUNLE · 2013 to 2025
$19.6MImmuno-Oncology Translation Network: Data Management and Resource-Sharing Center at RPCIU24CA232979 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI HUTSON, ALAN DAVID, LIU, SONG · 2018 to 2024
$8.9MU01 Proposal Transfer - 2021U01CA233085 · NCI · UNIVERSITY OF CHICAGO · PI GAMBOTTO, ANDREA, KOZBOR, DANUTA B · 2019 to 2019
$4.1MNetwork Lead Academic Participating Site Grant from the Roswell Park Cancer InstituteUG1CA233191 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI LELE, SHASHIKANT, LEVINE, ELLIS G · 2019 to 2025
$3.1MPostdoctoral Research Training in Surgical OncologyT32CA108456 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI YENDAMURI, SAIKRISHNA · 2006 to 2020
$2.8MmTOR inhibition for generating memory T cells to enhance ovarian tumor immunityR01CA158318 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI ODUNSI, KUNLE, SHRIKANT, PROTUL · 2011 to 2015
$1.7MInformatic Methods for Differential Signaling and Immune Co-Regulatory ExpressionK01LM012100 · NLM · ROSWELL PARK CANCER INSTITUTE CORP · PI ENG, KEVIN HASEGAWA · 2015 to 2017
$502kNCI NIH HHS P30 CA016056NCI NIH HHS P50 CA159981NCI NIH HHS R01 CA158318NCI NIH HHS T32 CA108456NCI NIH HHS U01 CA233085NCI NIH HHS U24 CA224319NCI NIH HHS U24 CA232979NCI NIH HHS UG1 CA233191NLM NIH HHS K01 LM012100
Abstract
CD8
Indexed as
ovarian cancerT-cell repertoiretumor immunity
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.